Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk

Newly published data show that participants maintained A1C and weight control up to two years in SURPASS-4, the largest and longest SURPASS trial completed to date No increased cardiovascular risk identified with tirzepatide; hazard ratio of 0.74 observed for MACE-4 events INDIANAPOLIS , Oct.